The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 Update- Original Invest

27 Oct 2006 15:56

AIM27 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Original Investments plc to be renamed ViaLogy PlcCOMPANY ADDRESS:Ashcombe Court Woolsack Way Godalming Surrey COMPANY POSTCODE:GU7 1LQCOUNTRY OF INCORPORATION:EnglandCOMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Original Investments plc is acquiring ViaLogy Corp ("ViaLogy"). This transaction constitutes a reverse takeoverfor the purposes of the AIM Rules. ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging theirprior expertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed atechnology to separate the background 'noise' that envelops weak signals called Quantum ResonanceInterferometry (QRI). The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able to detect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square)background noise. The technology was the subject of further development work undertaken in the massspectrometry industry. Other development activities were carried out in the areas of sensor data processing andtransference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be ofconsiderable benefit in a number of industrial areas and a planned programme of commercialisation hascommenced. Discussions at both development and commercial levels are being held with a number of internationalcompanies and national authorities to verify the suitability of incorporating the ViaLogy technology intoexisting and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price towhich it seeks admission and the number and type to be held as treasury shares):403,256,437 ordinary shares with a nominal value of 0.01p per share and an issue price of 4p per share.CAPITAL TO BE RAISED ON ADMISSION:N/AFULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors James Derrick Slater, Chairman (to resign on Admission) Terence Bond, Managing Director and Deputy Chairman (to become Executive Chairman on Admission) Dr Richard Peter Dixey, Non Executive Director (Richard is due to retire at the AGM) Julian George Viggars, Non Executive Director (to resign on Admission) Proposed Directors Michael Woods Kelly, Proposed Chief Executive Dr Sandeep Gulati, Proposed Technical Director George Rehm, Proposed Non-Executive Director Dr Robert William Dean, Proposed Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARECAPITAL BEFORE AND AFTER ADMISSION: Shareholding Before Admission % Shareholding After Admission % James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIMRULES:N/AANTICIPATED ACCOUNTING REFERENCE DATE:31 MarchEXPECTED ADMISSION DATE:31 October 2006NAME AND ADDRESS OF NOMINATED ADVISER:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELNAME AND ADDRESS OF BROKER:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELDETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELDATE OF NOTIFICATION: 27 October 2006NEW/ UPDATE (see note):Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.